PDS Biotechnology (PDSB) Set to Announce Quarterly Earnings on Thursday

Posted by Lars Charter on Nov 7th, 2024

PDS Biotechnology (NASDAQ:PDSB – Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Thursday, November 14th. Analysts expect PDS Biotechnology to post earnings of ($0.29) per share for the quarter.

PDS Biotechnology (NASDAQ:PDSB – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.08. During the same period in the previous year, the company earned ($0.37) EPS. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PDS Biotechnology Price Performance

PDSB stock opened at $3.23 on Thursday. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.45. PDS Biotechnology has a fifty-two week low of $2.53 and a fifty-two week high of $6.85. The business has a 50 day moving average price of $3.25 and a 200 day moving average price of $3.28. The stock has a market cap of $118.93 million, a price-to-earnings ratio of -2.65 and a beta of 1.93.

Wall Street Analyst Weigh In

Several research analysts have commented on PDSB shares. StockNews.com raised PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research report on Thursday, October 24th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, PDS Biotechnology has an average rating of “Buy” and a consensus target price of $14.25.

View Our Latest Report on PDSB

PDS Biotechnology Company Profile

(Get Free Report)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.